| | Variables | Effect on recurrent hepatitis C |
| | Donor and graft factors | | | Age [17, 37–43] | More severe disease (>40, >50, >65) | | Steatosis [56, 57, 76–79] | Few studies | | Prolonged ischemic time [54, 55, 80–83] | More severe disease | | HCV+ graft [6, 22, 40, 50–53, 76] | No influence | | Reduced size versus whole liver (LDLT versus DDLT) [39, 84–95] | No difference | | Pretransplant recipient factors | | | Genotype 1b [8, 32, 33, 35, 40] | Controversial | | Pre-LT higher viral load [21, 28, 96, 97] | Unclear | | Age [32, 44, 98] | Few studies | | Race [45, 46, 99] | Few studies | | Sex [20, 47, 48] | Few studies | | HIV coinfection [100–107] | No influence | | IL-28B gene polymorphism [49, 108–111] | More severe disease in CT and TT genotype | | Posttransplant recipient factors | | | Post-LT higher viral load [10, 27–31] | More severe disease | | CMV infection [22, 29, 32, 112–116] | Unclear | | Diabetes mellitus (Metabolic syndrome) [29, 117–121] | More severe disease | | Immunosuppression | | | Steroid bolus/OKT3 [6, 21, 22, 58, 59, 122–124] | More severe disease | | Maintenance steroid [34, 60–62, 122] | Severe disease when rapidly tapered | | Steroid free regimen [63–68, 125–127] | No influence | | Tacrolimus versus cyclosporine [69–75] | No difference | | Anti-IL-2 receptor antibodies [63, 126, 128–131] | Controversial | | Azathioprine/mycophenolate mofetil [132–140] | Controversial | | mTOR inhibitors [141–143] | Few studies |
|
|
